← Oncology Approval Tracker

FDA DECISION ·

Polivy + bendamustine + rituximab product

polatuzumab vedotin-piiq + bendamustine + rituximab product · Genentech

Traditional approvalTraditional conversionLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory DLBCL not otherwise specified after at least two prior therapies, in combination with bendamustine and a rituximab product.

LAMPGEN ANALYSIS

Why it matters

This action converted the earlier accelerated later-line approval. FDA separately approved a first-line regimen on the same date.

What research teams should watch

Document prior lines and the correct treatment backbone when reconciling the two April decisions.

PRIMARY RECORDS

Sources